In this podcast, Thomas Hoffman, Managing Director at Solebury Trout, an investor relations and communications advisory firm, and Joseph Oakenfold in Deutsche Bank's depository receipts team explain why life sciences companies are more than just flashes in the pan, but will be here to stay long after the new normal has been reached. They also share why Asian and European healthcare companies see the US as integral to their investment strategy